RDY News & Events

Dr. Reddy's Laboratories announced that the FDA has accepted for review, its 351 (k) Biologics License Application IV for infusion formulation for DRL_AB, a proposed interchangeable biosimilar to ORENCIA that was submitted in December 2025. "We are proud to be the first to submit a BLA for an abatacept biosimilar which marks a significant milestone in our mission to increase patient access to critical, high-quality biologic therapies," said Milan Kalawadia, CEO, North America, at Dr. Reddy's. "We look forward to working with the FDA to bring this in-house developed biosimilar to market as a cost-effective alternative for patients and healthcare providers in the United States." DRL_AB, once approved will be administered as an IV for infusion formulation for the treatment of adults with moderately-to-severely active rheumatoid arthritis, adults with active psoriatic arthritis, and individuals aged six years and above with moderately-to-severely active polyarticular juvenile idiopathic arthritis. The 351 (k) BLA submission includes a comprehensive data package consisting of analytical, pharmacokinetic, and clinical studies.

Coya Therapeutics (COYA) announced that it has entered into a definitive securities purchase agreement for the purchase and sale of an aggregate of 2.522M shares of its common stock in a private placement at a price of $4.40 per share. The offering is expected to close on or about January 30, subject to the satisfaction of customary closing conditions. The investors in the offering are Dr. Reddy's (RDY), $10M, and Greenlight Capital, an existing institutional stockholder of the company. The gross proceeds to the Company from the private placement are expected to be approximately $11.1M, before deducting offering expenses payable by the company. No broker, placement agent or investment banker was engaged in the transaction. The company intends to use the net proceeds to accelerate tech transfer and scale-up manufacturing activities for low dose IL-2 to support the commercial readiness of COYA 302.

The major averages had a down day as markets brace for the Federal Reserve's rate-decision later this week. The core of sentiment seems driven by widespread expectations that the Fed will deliver a 25 basis-point cut, though there still remains unease under the surface. The challenge facing the Fed given uncertainty over what constitutes a "neutral" interest rate could make this week's meeting contentious.Looking to commodities, gold was fractionally lower, while oil dropped to below $60 per barrel.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:IBMConfluentfor $31 per share, or a total enterprise value of $11BParamount Skydancehasof $30 per share for all of Warner Bros. Discoveryfollowing Netflix'sdeal with the company late last week and the company said it will advise on its board recommendation on Paramount's bid within 10 daysJPMorganChasehas named Todd Combs, Investment Manager of Berkshire Hathaway, to head theof the firm's new Security and Resiliency InitiativePresident Trump said anis coming this weekMicrosoftis in talks to design custom chips with Broadcom,2. WALL STREET CALLS:Morgan Stanley analyst Andrew PercocoTeslato Equal Weight and upgraded General Motorsto Overweight as the firm adjusted ratings in the autos and shared mobility group following a change in analystsMorgan Stanley's Percoco alsoRivianand to Lucid Groupto UnderweightBenchmarkMarvellto Hold, citing "a high degree of conviction" that the company has lost both Amazon'sTranium 3 and 4 designs to its Taiwanese competitorPivotal Research and RosenblattNetflixto Neutral-equivalent ratings after the "surprise announcement" of an agreement to acquire Warner Bros.'studios and HBO businessesHSBCVisaand MasterCardto Buy3. AROUND THE WEB:PepsiCowill look at its North American supply chain as one of a number of steps it is taking to complete talks with activist investor Elliott Investment Management,NextEra Energyand Exxon Mobilare developing a 1.2 gigawatt data center for a hyperscaler,Metais delaying the release of its mixed-reality glasses codenamed "Phoenix" from the second half of 2026 to the first half of 2027,South Korea's industry ministry and Arm Holdingshave signed an agreement to strengthen the nation's semiconductor and AI sectors, according to a presidential policy adviser,Eli Lilly'sMounjaro will be added to China's state-run health insurance scheme for patients with type 2 diabetes beginning January 1,4. MOVERS:Wave Life Sciencesincreases in New York after announcing data from itsStructure Therapeuticsgains after reporting data from theImmutephigher in New York afterwith Dr. Reddy'sfor Eftilagimod AlfaLegend Biotechfalls after announcing newCoreWeavelower after5. EARNINGS/GUIDANCE:Kamadareiterated itsTreasure Globalfor FY26Byrna Technologiesreportedand provided guidance for FY25Virco, with EPS and revenue lower year-over-yearOracleon December 10INDEXES:The Dow fell 215.67, or 0.45%, to 47,739.32, the Nasdaq lost 32.22, or 0.14%, to 23,545.90, and the S&P 500 declined 23.89, or 0.35%, to 6,846.51.

The major averages were lower near noon as markets brace for the Federal Reserve's rate-decision later this week. The core of sentiment seems driven by widespread expectations that the Fed will deliver a 25 basis-point cut, though there still remains unease under the surface. The challenge facing the Fed given uncertainty over what constitutes a "neutral" interest rate could make this week's meeting contentious.Looking to commodities, gold was fractionally lower near noon, while oil dropped to below $60 per barrel.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:IBMConfluentfor $31 per share, or a total enterprise value of $11BParamount Skydancehasof $30 per share for all of Warner Bros.following Netflix'sdeal with the company late last weekJPMorganChasehas named Todd Combs, Investment Manager of Berkshire Hathaway, to head theof the firm's new Security and Resiliency InitiativePresident Trump said anis coming this weekMicrosoftis in talks to design custom chips with Broadcom,2. WALL STREET CALLS:Morgan Stanley analyst Andrew PercocoTeslato Equal Weight and upgraded General Motorsto Overweight as the firm adjusted ratings in the autos and shared mobility group following a change in analystsMorgan Stanley's Percoco alsoRivianand to Lucid Groupto UnderweightBenchmarkMarvellto Hold, citing "a high degree of conviction" that the company has lost both Amazon'sTranium 3 and 4 designs to its Taiwanese competitorPivotal Research and RosenblattNetflixto Neutral-equivalent ratings after the "surprise announcement" of an agreement to acquire Warner Bros.'studios and HBO businessesHSBCVisaand MasterCardto Buy3. AROUND THE WEB:Metais delaying the release of its mixed-reality glasses codenamed "Phoenix" from the second half of 2026 to the first half of 2027,South Korea's industry ministry and Arm Holdingshave signed an agreement to strengthen the nation's semiconductor and AI sectors, according to a presidential policy adviser,Eli Lilly'sMounjaro will be added to China's state-run health insurance scheme for patients with type 2 diabetes beginning January 1,Anuradha Mittal, the chair of Ben & Jerry's independent board, said she has no plans to resign despite pressure from Unileverahead of Monday's public spinoff of its Magnum division,Apple's (AAPL) Johny Srouji, who oversees the company's chip division, told staff that he's staying at the company,4. MOVERS:Wave Life Sciencesincreases in New York after announcing data from itsStructure Therapeuticsgains after reporting data from theImmutephigher in New York afterwith Dr. Reddy'sfor Eftilagimod AlfaLegend Biotechfalls after announcing newCoreWeavelower after announcing a5. EARNINGS/GUIDANCE:Kamadafor FY25Treasure Globalfor FY26Byrna Technologiesand provided guidance for FY25Virco, with EPS and revenue lower year-over-yearOracleon December 10INDEXES:Near midday, the Dow was down 0.44%, or 212.24, to 47,742.75, the Nasdaq was down 0.20%, or 46.99, to 23,531.14, and the S&P 500 was down 0.36%, or 24.77, to 6,845.63.